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Xenobiotic-mediated induction of cytochrome P450 (CYP) drug metabolizing enzymes
(DMEs) is frequently encountered in drug discovery and can influence disposition,
pharmacokinetic, and toxicity profiles. The CYP1A subfamily of DMEs plays a central role
in the biotransformation of several drugs and environmental chemicals. Autoinduction of
drugs through CYP3A enzymes is a common mechanism for their enhanced clearance.
However, autoinduction via CYP1A is encountered less frequently. In this report, an
experimental compound, A-998679 [3-(5-pyridin-3-yl-1,2,4-oxadiazol-3-yl) benzonitrile], was
shown to enhance its own clearance via induction of Cyp1a1 and Cyp1a2. Rats were
dosed for 5 days with 30, 100, and 200mg/kg/day A-998679. During the dosing period,
the compound’s plasma AUC decreased at 30mg/kg (95%) and 100mg/kg (80%). Gene
expression analysis and immunohistochemistry of the livers showed a large increase in
the mRNA and protein levels of Cyp1a, which was involved in the biotransformation of
A-998679. Induction of CYP1A was confirmed in primary rat, human, and dog hepatocytes.
The compound also weakly inhibited CYP1A2 in human liver microsomes. A-998679
activated the aryl hydrocarbon receptor (AhR) in a luciferase gene reporter assay in HepG2
cells, upregulated expression of genes associated with AhR activation in rat liver and
enhanced nuclear migration of AhR in HepG2 cells. Collectively these results demonstrate
that A-998679 is an AhR activator that induces Cyp1a1 and Cyp1a2 expression, resulting
in an autoinduction phenomenon. The unique properties of A-998679, along with its novel
structure distinct from classical polycyclic aromatic hydrocarbons (PAHs), may warrant
its further evaluation as a tool compound for use in studies involving AhR biology and
CYP1A-related mechanisms of drug metabolism and toxicity.
Keywords: aryl hydrocarbon receptor, cytochrome P450, autoinduction
INTRODUCTION
Cytochrome P450 (CYP) induction in the liver complicates
the development of new drugs in pharmaceutical industry
because of its association with drug–drug interactions and its
potential impact on toxicology studies (Coon, 2005; Amacher,
2010). Multiple enzymes and transporters involved in xeno-
biotic metabolism are inducible through activation of various
transcription factors, most notably the aryl hydrocarbon recep-
tor (AhR), the pregnane X receptor (PXR), the peroxisome
proliferator-activated receptor (PPARα), and the constitutive
androstane receptor (CAR) (Blomme et al., 2009). The acti-
vated receptors, along with specific cofactors, localize to their
respective DNA response elements, leading to transcription and
translation of their target genes, including CYPs, transporters,
and phase 2 conjugation enzymes (e.g., Uridine 5′-diphospho-
glucuronosyltransferases-UGTs). AhR activation regulates the
transcription of CYP1A1 and CYP1A2 and several other genes
(Nebert and Dalton, 2006). When AhR encounters a suitable
ligand, its chaperone proteins [including heat shock protein 90
(HSP90), p23, and aryl hydrocarbon receptor interacting protein
(ARA9)] are displaced, leading to migration to the nucleus where
AhR forms a heterodimer with aryl hydrocarbon receptor nuclear
translocator (ARNT) with subsequent DNA binding at the dioxin
response element (DRE or XRE) and transcriptional activation
(Nebert and Dalton, 2006; Barouki et al., 2007). While this may
represent the predominant mechanism, data indicate that induc-
tion of CYP1A may not be only driven by AhR binding and that
more complex cross talk can be involved (Hu et al., 2007).
AhR activation by toxicants, such as 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD), has been associated
with multiple undesirable side effects, such as wasting syndrome,
chloracne, reactive metabolite formation, mutagenic potential,
and other severe toxicities. The direct role of CYP1A in many
toxicities remains the subject of investigation and discussion, but
it has been clearly associated with reactive metabolite formation,
increased oxidative stress, and vascular dysfunction (Kopf et al.,
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2010; Denison et al., 2011). In the cases of omeprazole and other
related drugs considered relatively safe, recent evidence suggests
that the toxicity potential resulting from activation of AhR and
CYP1A induction is complex and involves multiple factors,
including the ligand affinity to AhR, genetics, environmental
exposure, pharmacokinetics (PK), or smoking status (Ma and
Lu, 2007; Mitchell and Elferink, 2009). For these reasons, the
significance of AhR activation in pharmaceutical risk assessment
has been the subject of debate.
Increased activity of a specific CYP can result in an increased
systemic elimination of a xenobiotic. This phenomenon can
complicate the determination of proper clinical dosages and
safety margins, can lead to decreased efficacy over time, and
increases the likelihood of the formation of reactive oxygen
species (Hewitt et al., 2007). CYP3A isoenzymes are most com-
monly associated with autoinduction (Zhu, 2010). For instance,
carbamazepine, dexamethasone, lovastatin, and rifabutin induce
expression of CYP3A4 and are also metabolized by the enzyme
(Zhu, 2010).
There are fewer reports of CYP1A1 and CYP1A2 involvement
with xenobiotic autoinduction, despite its participation in the
metabolism of a diverse array of drugs and environmental chemi-
cals (Ma and Lu, 2007). Polycyclic aromatic hydrocarbons (PAHs)
are one class of compounds that are both induced and metabo-
lized by the CYP1A subfamily, which in turn can be responsible
for the production of several reactive metabolites promoting
tumor formation (Barouki and Morel, 2001), but other authors
have noted that CYP1A may also have a protective and adap-
tive role in whole animals (Nebert et al., 2004). However, the
most potent inducer of CYP1A, TCDD, is a poor substrate of
the enzyme (Ma and Lu, 2007). Omeprazole, a drug that induces
CYP1A in humans, is also not metabolized by the enzyme (Diaz
et al., 1990; Ma and Lu, 2007).
In this report, we describe an experimental activator of
AhR resulting in autoinduction through Cyp1a1 and Cyp1a2.
A-998679 [3-(5-pyridin-3-yl-1,2,4-oxadiazol-3-yl) benzonitrile]
(Figure 1) is an experimental compound that underwent early
preclinical characterization for neuropsychiatric indications. It is
a novel positive allosteric modulator of α4β2 nicotinic acetyl-
choline receptors, enhancing the downstream response of these
receptors as described previously (Anderson et al., 2009).
In pharmacokinetic studies, repeated dosing was associated
with lower plasma exposure over time. The objective of this
study was to generate a mechanistic understanding of this phe-
nomenon.
FIGURE 1 | Chemical structure of A-998679.
MATERIALS ANDMETHODS
REAGENTS
A-998679 was synthesized in our laboratories. All reagents,
including the probe substrates phenacetin, diclofenac, and
dextromethorphan, were obtained from Sigma (St Louis, MO)
unless otherwise indicated. Midazolam was purchased from
Spectrum Labs (Rancho Dominguez, CA); S-Mephenytoin was
from Toronto Research Chemical (Toronto, Canada).
RAT STUDY
All animal experiments were conducted in accordance with
the Guiding Principles in the Use of Animals in Toxicology
(http://www.toxicology.org/ai/air/air6.asp) and were approved
by Abbott’s Institutional Animal Care and Use Committee
(IACUC). Male Sprague-Dawley rats [Crl:CD®(SD)IGS BR],
weighing ∼250 g at study initiation were obtained from Charles
River Laboratories, Inc. (Wilmington, MA). Rats were housed
singly in ventilated, stainless steel, wire-bottom hanging cages
and fed non-certified Rodent Chow (Harlan Labs, Madison,
WI), and water ad libitum and acclimated for at least 5 days
after arrival. Rats were randomly assigned to various treatment
groups (3 rats/group) and were dosed once daily by oral gavage
with vehicle (0.2% hydroxypropylmethylcellulose at a dose vol-
ume of 10ml/kg) or with 30, 100, or 200mg/kg of A-998679.
All rats were fasted overnight after their last dose, weighed and
sacrificed under isoflurane anesthesia. For histopathological eval-
uation, liver, heart, kidney, spleen, bone (sternum) with marrow,
gastrointestinal tract (duodenum with pancreas, jejunum, ileum,
cecum, and colon), thymus, and lung were fixed in formalin,
routinely processed, and embedded in paraffin. Paraffin sections
(4μm) were stained with hematoxylin and eosin. Liver and small
intestine (jejunum) were also flash frozen in liquid nitrogen
and stored at −80◦C until processing for gene expression profil-
ing. Serum clinical chemistry parameters were quantified using
an Aeroset Clinical Chemistry Analyzer (Abbott Laboratories,
Abbott Park, IL) and included alanine amino transferase (ALT),
aspartate amino transferase (AST), gamma glutamyltransferase
(GGT), and alkaline phosphatase (ALP) activities.
CELL CULTURE
Rat hepatocytes were isolated in a perfusion procedure as
described previously (Elliget and Kolaja, 1983; Waring et al.,
2001). The beagle dog hepatocytes were isolated in the same
manner, except for adjustment of flow rate and buffer volume
to scale to liver size. Cells were plated at a seeding density of
1.0 × 106 cells per well on 6-well, collagen-type I coated plates
(BD Biosciences, Bedford, MA) in hepatocyte plating medium
(Celsis, Baltimore, MD). Cells were allowed to attach for 24 h
in a 37◦C humidified incubator with a 5% CO2 atmosphere
and were dosed for 24 h (rat) or 48 h (dog) with vehicle control
[0.1%DMSO (v/v)] or 10μMA-998679 in fresh treatment media
(Celsis hepatocyte incubation media) every 24 h. After the last
incubation, cells were lysed in 1ml of Qiazol (Qiagen) and stored
at −80◦C until RNA isolation. Cryopreserved human hepato-
cytes (donor designation Hu4198; Invitrogen Life Technologies,
Carlsbad, CA) were thawed and plated according to the manufac-
turer’s protocol and allowed to incubate for 24 h. Cells were then
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dosed with 1, 3, 10 or 30μM A-998679 for 24 h and harvested as
described above. HepG2 cells (American Type Culture Collection,
Manassas, VA) were cultured under the same conditions as the
hepatocytes using Dulbecco’s Modified Eagle’s Medium supple-
mented with 10% fetal calf serum (Invitrogen Life Technologies).
The cells were cultured continuously until used in experiments.
RNA PREPARATION
Frozen liver or jejunum were immediately added to 4ml of
TRIzol reagent (Invitrogen Life Technologies) and homogenized
using a Polytron 300D homogenizer (Brinkman Instruments,
Westbury, NY). Total RNA was isolated via chloroform extrac-
tion and nucleic acid precipitation with isopropanol. Pellets were
washed with 75% ethanol and re-suspended in molecular biology
grade water. Nucleic acid concentration was determined by OD
260 nm (Smart-Spec, Bio-Rad Laboratories, Hercules, CA), and
RNA integrity was evaluated using an Agilent 2100 bioanalyzer
(Agilent Technologies, Foster City, CA).
MICROARRAY HYBRIDIZATION
Microarray hybridization was performed using the standard
protocol provided by Affymetrix, Inc. (Santa Clara, CA).
Briefly, approximately 5μg of total RNA was reverse tran-
scribed into cDNA using a Superscript II Double-Strand
cDNA synthesis kit (Invitrogen Life Technologies) according
to the manufacturer’s instructions, except that the primer
used for the reverse transcription reaction was a modified
T7 primer with 24 thymidines at the 5′ end (Affymetrix).
The sequence was 5′-GGCCAGTGAATTGTAATACGAC-
TCACTATAGGGAGGCGG-(dT)24-3′ . cDNA was purified via
filtration (Qiagen, Valencia, CA), phenol/chloroform/
isoamylalcohol extraction (Invitrogen Life Technologies)
and ethanol precipitation. Purified cDNA was re-suspended
in molecular biology grade water, and then used to synthesize
biotin-labeled cRNA using the Enzo RNA Transcript Labeling Kit
(Enzo Life Sciences, Farmindale, NY) according to the manufac-
turer’s instructions. Labeled cRNA was purified using RNeasy
kits (Qiagen), and cRNA concentration and integrity were
evaluated. Approximately 200μg of cRNA was then fragmented
in a solution of 40mM Tris-acetate, pH 8.1, 100mM KOAc,
and 30mM MgOAc at 94◦C for 35min, and then hybridized
to an Affymetrix rat genome RAE230 2.0 array, which contains
sequences to roughly 31,000 probe sets, at 45◦C overnight using
an Affymetrix Hybridization Oven 640. Arrays were subsequently
washed, stained twice with strepavidin-phycoerythrin (Molecular
Probes, Carlsbad, CA) using the GeneChip® FluidicsWorkstation
400 (Affymetrix), and finally scanned using the Affymetrix
GeneChip® Scanner 3000.
STATISTICS AND MICROARRAY DATA ANALYSIS
Microarray data were analyzed using Rosetta Resolver software
using its error model to detect statistically significant (p ≤ 0.05)
gene expression changes (version 7.2). The microarray data have
been deposited in NCBIs Gene Expression Omnibus and are
accessible through GEO Series accession number GSE39525. Data
were analyzed through the use of IPA (version 9.0, Ingenuity®
Systems, www.ingenuity.com). (Redwood City, CA). Graphpad
Prism (version 5.0; Graphpad Software, Inc., San Diego, CA)
was used for graphing and statistical analysis, including the stan-
dard t-test and One-Way ANOVA followed by Tukey’s multiple
comparison test. A p-value ≤ 0.05 was considered significant.
PHARMACOKINETIC ANALYSIS
Serial blood samples were obtained from a tail vein of each
rat 0.5, 1.5, 3, 6, 9, 12, and 24 h after drug administration on
the first and last day of dosing. Plasma was separated by cen-
trifugation and stored frozen prior to analysis. A-998679 was
separated from the plasma using protein precipitation with ace-
tonitrile. A-998679 and the internal standard were separated
from co-extracted contaminants on a 50 × 3mm Betasil CN
column (Thermosystem) with an acetonitrile: 10mM ammo-
nium acetate mobile phase (35:65, by volume) at a flow rate
of 0.4ml/min at ambient temperature. Concentrations of A-
998679 in the plasma extracts were determined by HPLC-MS/MS
(API2000; Applied Biosystems). Peak plasma concentrations
(Cmax) and the time to peak plasma concentration (Tmax) were
read directly from the plasma concentration data for each rat.
A-998679 plasma concentration data were submitted to multi-
exponential curve fitting using WinNonlin. The area under the
plasma concentration-time curve from 0 to t hours (time of
the last measurable plasma concentration) after dosing (AUC0-
t) was calculated using the linear trapezoidal rule for the plasma
concentration-time profiles. The residual area extrapolated to
infinity, determined as the final measured plasma concentra-
tion (Ct) divided by the terminal elimination rate constant (β),
was added to AUC0-t to produce the total area under the curve
(AUC0-∞).
METABOLIC PROFILING OF A-998679
Identification of the drug metabolizing enzymes (DMEs) of A-
998679 was studied in cDNA expressed recombinant enzymes
prepared from baculovirus infected insect cells over-expressing
rat Cyp isoforms (BD Gentest, Woburn, MA) as listed in Table 2.
Incubations were conducted in duplicate using Supersomes. The
incubation mixture contained 100 pmol/ml of enzymes, except
for Cyp1a1 (200 pmol/ml), 0.1 or 0.21μM of [3H]A-998679 in
100mM phosphate buffer (pH 7.4). Reactions were initiated
with the addition of NADPH at a final concentration of 1mM
and incubated at 37◦C for 60min. At the end of the incuba-
tion period, the incubations were terminated by the addition
of acetonitrile/ethanol (50/50, v/v) solution. Insect control sam-
ples lacking expressed enzyme were used as negative control.
The degree of metabolism of A-998679 was assessed by percent
of parent remaining using the radio-HPLC method described
below.
To assess the involvement of CYP1A2 in the metabolism of
A-998679, incubations were conducted in duplicate in human
liver microsomes (BD Gentest, Lot # 20567) in the presence
or absence of furafylline, a CYP1A2 inhibitor. The incuba-
tion mixture contained 0.34μM [3H]A-998679 and 0.5mg/ml
liver microsomal protein in 50mM phosphate buffer at pH 7.4.
Varying concentrations (final concentrations of 0, 0.625, 1.25,
2.5, 5, or 10mM) of furafylline were co-incubated with [3H]A-
998679. The reactions were initiated by the addition of 1mM
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NADPH and incubated at 37◦C for 30min. The reaction was
quenched with acetonitrile and methanol (50/50, v/v). Samples
were centrifuged for 10min at 14,000 rpm (Jouan CR3i cen-
trifuge, Virginia with an AC 2.14 rotor), and the supernatants
were analyzed by HPLC with radioflow detection. The degree of
inhibition of A-998679 metabolism was determined relative to
negative control samples.
Radiolabeled components from the above assays were pro-
filed following separation by HPLC with on line radioflow
detector. The system consisted of an Agilent 1100 Series qua-
ternary pump and autosampler connected to a Packard 500TR
flow scintillation detector. The data were processed using the
Radiomatic™ Flo-one® software v3.65. The scintillant (Perkin
Elmer FLO-SCINT™ III) flow was maintained at 3ml/min. The
elution of metabolites was achieved at room temperature on a
Luna C18, 5μm, 100A, 250 × 4.6mm i.d. column in the presence
of a guard column (Phenomenex, Torrance, CA). Mobile phases
were A: 25mM ammonium formate in water with 2.5%methanol
(v/v) pH 3.5; and B: acetonitrile; the flow rate was maintained at
1ml/min. The gradient program began at 0% B at 0min and was
increased linearly to 60% B in 25min, to 85% B in 5min, then
decreased to 0% B in 2min.
RT-PCR
RNA samples were diluted with RNase-free molecular biology
grade water to a concentration of 20 ng/μl total RNA. Each sam-
ple (2.5μl) was pipetted in triplicate into a 96-well optical reac-
tion plate (Applied Biosystems, Carlsbad, CA). Reagent mix was
made using the TaqMan EZ RT–PCR kit (Applied Biosystems)
and 17.5μl of reagent mix was added to each well. PCR primer
and TaqMan probe sequences are listed in Table A1. RT–PCR was
performed on the ABI Prism 7900 (Applied Biosystems) with
the following parameters: 2min at 50◦C (initial step), 30min at
60◦C (RT), 5min at 95◦C (deactivation), and 40 cycles of 20 s
melting at 94◦C then 1min annealing/extending at 62◦C. Results
were analyzed by calculating the fold change of CYP1A1 and/or
CYP1A2 mRNA levels normalized to 28S rRNA (Ct) in com-
pound treated cells or tissues compared to vehicle levels. Since
Cyp1a1 was undetectable in vehicle livers, an arbitrary Ct = 40
was assigned and used as a basis to calculate fold change.
IMMUNOHISTOCHEMISTRY
Formalin fixed, paraffin embedded 4μm sections were rehy-
drated through 100 and 95% ethanol and deionized water.
Endogenous peroxidase activity was quenched by incubating
slides in 3% hydrogen peroxide followed by a brief rinse in Tris
buffered saline (TBS). No antigen retrieval was used. Sections
were blocked with SNIPER (Biocare, Concord, CA) for 5min
and incubated for 1 h with a 1:900 diluted polyclonal rabbit
anti-rat Cyp1a1 antibody (Millipore-Chemicon, Temecula, CA).
After a TBS wash, the sections were incubated for 30min with
a 1:200 diluted biotinylated goat anti-rabbit secondary antibody
(Vector Laboratories, Burlingame, CA). After a brief wash in TBS,
the sections were treated for 30min with ABC reagent (Vector
Laboratories), washed in TBS, and then incubated with DAB
(3,3′-diaminobenzidine) (Vector Laboratories) for 5min. Slides
were counterstained with hematoxylin and mounted for viewing.
All procedures were conducted at room temperature.
AhR REPORTER ASSAY
HepG2 cells were transiently transfected overnight with the
construct (1200 bp portion of the human CYP1A1 promoter
region containing 2 copies of the functional consensus sequence
for the DRE in luc2P luciferase vector (SwitchGear Genomics
cat# 114555, Menlo Park, CA) using lipofectin (Invitrogen Life
Technologies) at 500 ng construct per million cells. Following
transfection, the cells were replated in a 96-well format and
dosed for 24 h with 0.1% (v/v) DMSO vehicle, 3-MC at 0.05,
0.1, 0.5, 1, 5, 10μM, and A-998679 at 1.5625, 3.125, 6.25,
12.5, 25, and 50μM. Luminescence signal was generated using
the Dual-Luciferase Reporter Assay System (Promega, Madison,
WI) and detected with a Tecan Genios Pro reader (Männedorf,
Switzerland).
TRANSLOCATION ASSAY
HepG2 cells were plated in Lab-Tek II Chamber slides (Nalgene,
Rochester, NY) at a seeding density of 50,000 cells/well. The cells
were allowed to attach overnight and were treated for 2 h or
24 h with 10 or 40μM A-998679, 2μM 3-methylchloranthrene
(3-MC) as a positive control, or 0.1% (v/v) DMSO vehicle.
The cells were fixed in fresh 3% paraformaldehyde solution
in PBS followed by a PBS wash, and were then permeabi-
lized for 5min using 0.2% Triton X-100 in PBS followed by
another PBS wash. The cells were then incubated with block-
ing buffer consisting of 1% BSA/PBS solutions and immediately
incubated with a 1:50 dilution of rabbit polyclonal antibody to
AhR (Abcam, Cambridge, MA catalog# 63636) for 1 h at 37◦C.
Cells were then washed with PBS, re-blocked for 10min, and
stained with an Alexa 546 donkey anti-rabbit secondary anti-
body (diluted 1:200; Invitrogen Life Technologies) for 45min
at 37◦C. The cells were then washed with PBS, stained with
0.5μMHoescht solution for 15min, and again washed with PBS.
The chamber slides were sealed and examined under the micro-
scope. Images were acquired with a SPOT RT SE digital camera
(Diagnostic Instruments, Sterling Heights, MI) mounted on a
Leica (Wetzlar, Germany) DMIRE inverted florescence micro-
scope using a 20× objective. Image acquisition was done using
Metamorph® software (Molecular Devices, Sunnyvale, CA) and
percent translocation of the AhR probe was quantitated using
MetaXpress (Molecular Devices). Twenty microscope fields were
evaluated per well (∼3000–6000 cells/well).
CYP INHIBITION EVALUATION
Incubations were performed in human liver microsomes using
probe substrate concentrations similar to their corresponding
Km values. Enzyme activity was evaluated in the presence of
various concentrations of A-998679. The incubations consisted
of the test article at varying concentrations (0–30μM), probe
substrate (concentration∼Km, see Table A2), human liver micro-
somal protein and 1mM NADPH in 50mM phosphate buffer
at pH 7.4. The specific incubation conditions for the CYP iso-
form evaluated are listed in Table A2. Relative quantitation of the
metabolites was obtained by LC-MS/MS using an ABSciex (Foster
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City, CA) API3000 or API4000 Qtrap hybrid linear ion trap mass
spectrometer equipped with a TurboIonspray source using either
PerkinElmer series 200 pumps or Agilent 1100 series pump with a
Leap autosampler. Analytes were separated using a Phenomenex
Prodigy ODS(3) 5μm, 50 × 2.0mm column at 50◦C, eluted and
detected under the specific conditions listed in Tables A3,A4, and
A5. The analyte to internal standard peak area ratios were deter-
mined using Analyst 1.4 software (Applied Biosytems, Carlsbad,
CA). The peak area ratios observed in the presence of test arti-
cle were compared to the vehicle control in order to determine
percent activity. To determine the IC50, the data were plotted as
Log [dose] μM vs. % inhibition, and analyzed with a sigmoidal
dose-response (variable slope) fitting equation. The inhibitory
responses observed for the positive controls were consistent with
historical values.
RESULTS
DOSING OF RATSWITH A-998679 FOR 5 DAYS RESULTS IN A
PROGRESSIVE DECLINE IN PLASMA EXPOSURE
Dosing of A-998679 in rats for 5 days resulted in a substantial
decline in Cmax at the 30mg/kg (88%) and 100mg/kg (53%)
dose levels (Figure 2) compared to the first day. AUC values were
decreased at 30mg/kg (95%) and 100mg/kg (80%) after 5 days
of dosing. There was a concurrent decrease in t1/2 and Tmax at
these dose levels (data not shown). Interestingly, no change in
AUC or Cmax was apparent at the highest dose tested (200mg/kg).
Correspondingly, there was a ∼25% increase in relative liver
weight in rats treated with 200mg/kg/day A-998679 but there was
no change at the lower doses. No significant changes were noted
in clinical chemistry parameters or histopathology.
A-998679 INDUCES Cyp1a1 AND Cyp1a2 IN RAT LIVER
Microarray analysis was used to profile changes in expression for
major Cyp isoenzymes in rat liver after 5 days of dosing with A-
998679. Cyp1a1 and Cyp1a2 were increased at the mRNA level in
at least one animal starting at the 100mg/kg dose (∼10–100-fold
and 2–3-fold, Cyp1a1 and Cyp1a2, respectively). No other major
gene expression changes were observed for other Cyp isoforms
(data not shown). Using RT-PCR, expression of rat Cyp1a1 and
Cyp1a2 mRNA was strongly induced in these livers at all doses
(Figure 3). Immunohistochemistry for Cyp1a1 confirmed induc-
tion (Figure 4). While Cyp1a1was not detectable in control livers,
immunostaining was observed at moderate levels in centrilob-
ular regions in rats dosed with A-998679. All gene expression
changes are provided in the supplementary material to this
article.
FIGURE 2 | A-998679 peak plasma concentrations (Cmax) and area under
the curve (AUC) following oral dosing of rats for 1 or 5 days. Plasma
levels are reported as the mean of 3 rats ± SEM in units of ng/ml (Cmax) or ng
• h/ml (AUC). The gray bars represent the compound levels on the first day of
dosing, and the red bars show the levels on the last day of dosing. The levels
drop over time except at the highest dose evaluated. Asterisks indicate that
the values were significantly different between day 1 and day 5 (∗p < 0.05,
∗∗p < 0.001).
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FIGURE 3 | Levels of Cyp1a1 and Cyp1a2 mRNA in livers from rats
dosed for 5 days with 30, 100, or 200mg/kg/day A-998679 compared to
vehicle control animals. The solid black bars represent Cyp1a1 levels (left
y-axis) from an individual rat while the shaded bars represent Cyp1a2 levels
(right y-axis). The mRNA data are expressed as fold-change (average ± SD)
compared to vehicle. Asterisks indicate that the values were significantly
different between treated and vehicle control rats (∗p < 0.05, ∗∗p < 0.001).
FIGURE 4 | Immunohistochemistry of Cyp1a1 in rat liver after 5 days of
treatment. (A) Vehicle control. (B) 200mg/kg/day A-998679. Darker areas
represent positive protein Cyp1a1 immunostaining.
A-998679 INDUCES CYP1A1 AND CYP1A2 IN HEPATOCYTESACROSS
SEVERAL SPECIES
To evaluate whether induction of CYP1A was relevant across
species, A-998679 was tested for both CYP1A1 and CYP1A2
mRNA induction in primary human hepatocytes as an in vitro
model. The compound induced both CYP1A mRNA isoforms in
a dose-dependent manner in human hepatocytes starting at lev-
els as low as 3μM (Figure 5). This result was also observed in
primary hepatocytes from rat for Cyp1a1 and dogs for CYP1A2
(data not shown). Thus, A-998679 does not have a species prefer-
ence with regard to its CYP1A inducing potential in this in vitro
hepatocyte model.
SMALL INTESTINE Cyp1a1 LEVELS ARE MILDLY UPREGULATED
BY A-998679
Since intestinal DMEs can also affect pharmacokinetic expo-
sure of agents dosed orally, the ability of A-998679 to induce
Cyp1a1 in rat jejunum was assessed (Figure 6). At doses of 30
and 100mg/kg, A-998679 treatment increased mRNA expres-
sion of Cyp1a1 with high interindividual variability, albeit at a
much lower level than in the liver. Interestingly, at the high dose
tested (200mg/kg), Cyp1a1 mRNA expression was significantly
decreased in the jejunum. Levels of jejunum Cyp1a2 mRNA
remained unchanged (data not shown).
FIGURE 5 | CYP1A1 and CYP1A2 levels in primary human hepatocytes
dosed with increasing levels of A-998679. The x-axis represents
concentration (μM), and the y-axis shows fold-change in CYP1A1 and
CYP1A2 mRNA (average ± SD) relative to vehicle control treated cells.
3MC (2μM) served as a positive control. The black bars represent CYP1A1
and the gray shaded bars indicate CYP1A2. Marked bars indicate that the
values were significantly different between treated and vehicle control
hepatocytes (∗p < 0.05, ∗∗p < 0.001).
FIGURE 6 | Levels of Cyp1a1 mRNA in small intestine (jejunum) from
rats treated with 30, 100, or 200mg/kg/day A-998679 compared to
vehicle control animals. The data presentation is the same as described in
Figure 3 (average ± SD). Note that at the 200mg/kg dose, the Cyp1a1
mRNA levels are substantially decreased (below the level of the vehicle
controls). Marked bars indicate that the values were significantly different
between treated and vehicle control rats (∗p < 0.05).
A-998679 IS AN ACTIVATOR OF AhR
A-998679 was evaluated for its ability to activate AhR. Using
rat liver mRNA profiling, the compound upregulated several
members of the AhR gene battery, including several glutathione
s-transferase (Gst) isoforms, NAD(P)H dehydrogenase, qui-
nine 1 (Nqo1), aldehyde dehydrogenase (Aldh), and AhR itself
(Figure 7A). Using a luciferase reporter assay with a construct
containing a consensus sequence from the human DRE trans-
fected in HepG2 cells, A-998679 activated AhR signaling in
a concentration dependent manner (EC50 = 16.2μM) with a
maximal increase of 56-fold over vehicle. 3-methylcholanthrene
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FIGURE 7 | (A) Representation of genes induced upon activation of AhR
and its subsequent binding to the DRE. Genes displayed as shades of
red were increased in mRNA expression, while those in shades of
green were decreased. Genes colored in white were not differentially
regulated. (B) Luciferase gene reporter assay correlating to the degree
of AhR activation in HepG2 cells. The concentration of A-998679 or the
positive control (3MC) is displayed on the x-axis. Activation of AhR
(average fold change ± SD) is indicated on the y-axis. (C) Representative
fluorescent photomicrograph of the subcellular localization of AhR relative
to the nucleus of HepG2 cells after 2 h treatment with vehicle, 3MC
(2μM), or A-998679 (40μM). AhR is stained pink and the nucleus is
stained blue. In the vehicle control, AhR staining was diffuse within the
cytoplasm. Upon treatment with 3MC or A-998679, AhR staining
intensifies in the nucleus, indicating active nuclear translocation of AhR.
The quantitation of nuclear AhR staining from this imaging experiment is
depicted in Table 1.
www.frontiersin.org October 2012 | Volume 3 | Article 213 | 7
Liguori et al. Mechanism of A-998679 autoinduction
(3MC), a prototypical AhR activator, served as a positive con-
trol (EC50 = 2.1μM; 97-fold maximum increase) (Figure 7B).
Therefore, 3MC was ∼8-fold more potent than A-998679 to acti-
vate AhR in this assay. To confirmAhR activation, translocation of
AhR from the cytoplasm to the nucleus in HepG2 cells was mon-
itored using fluorescent microscopy (Figure 7C). Both A-998679
at 40μM and 3MC at 2μM enhanced AhR nuclear staining rel-
ative to the vehicle control after 2 h of treatment (Table 1). The
% AhR positive cells dropped substantially after 24 h incubation,
but the levels of nuclear AhR remained slightly higher in the 3MC
and A-998679 treated cells compared to the vehicle control.
Cyp1a1 AND Cyp1a2 METABOLIZE A-998679
The ability of a panel of recombinant rat Cyps to metabolize
A-998679 was assessed (Table 2). Rat Cyp1a1 and Cyp1a2 were
involved in the metabolism of the compound, reducing the per-
cent parent remaining to 0%. Cyp2c11 and Cyp2b1 were also
contributors to the metabolism. Other various rat Cyps showed
little ability to metabolize the compound.
To further profile the involvement of human CYP1A2 in the
biotransformation of A-998679, the metabolic profile was evalu-
ated in vitro with human liver microsomes. Furafylline, a specific
inhibitor of human CYP1A2, was co-incubated with [3H]-A-
998679 and metabolism was monitored. As the concentration
of furafylline increased (Figure 8), there was a concurrent dose-
dependent decline in metabolism of A-998679 (IC50 = 0.7μM).
Based on these chemical inhibition data, it is reasonable to con-
clude Cyp1a2 is a primary contributor to metabolism of the
compound; the contribution from other Cyp subfamilies should
be minor. Taken together, the data suggest that Cyp1a1 and
Cyp1a2 are likely the major routes of metabolism for A-998679
in rats and humans.
A-998679 INHIBITS HUMAN CYP1A2
The inhibitory effect of A-998679 on the activity of selected CYP
isoforms in human liver microsomes was evaluated indirectly
by measuring the extent of inhibition of conversion of a probe
substrate to a specific metabolite whose formation is primarily
mediated by the isoform of interest. A-998679 showed no inhibi-
tion of the major CYP enzymes including 2C9, 2C19, 2D6, or 3A4
(IC50 > 30μM), but did inhibit CYP1A2 (IC50 = 0.46μM).
DISCUSSION
During a 5-day rat exploratory toxicology study, A-998679 dosing
resulted in decreased plasma levels and total exposure (AUC) of
the compound at 30 and 100mg/kg/day. Subsequent mechanistic
Table 1 | Quantitation of AhR nuclear translocation in HepG2 Cells.
Compound AhR nuclear staining (% positive cells)
2 h 24h
Vehicle control (0.1% DMSO) 15.6 3.4
2μM 3MC 26.3 11.1
10μM A-998679 18.8 4.5
40μM A-998679 29.6 6.3
investigation showed that A-998679 is an activator of AhR and an
inducer and substrate of Cyp1a. Higher doses (200mg/kg/day)
resulted in sustained levels of the compound, likely due to sat-
uration of metabolism. Hence, the exposure of A-998679 in
rats is determined by a delicate balance between induction of
Cyp1a at lower levels of the compound and saturation of Cyp1a
metabolism at higher levels with a possible enzyme inhibition
component (as demonstrated in human liver microsomes). At the
30mg/kg dose, the plasma concentration was low and enzyme
induction dominated the exposure level. As the dose and plasma
concentration increased, the metabolism capacity of Cyp1a was
overwhelmed and possibly inhibited, which counteracted the
effects of induction. This effect results in undesirable pharma-
cokinetic behavior since the plasma exposure cannot be reliably
predicted.
Gene expression profiling showed that, aside from the Cyp1a
subfamily, no other drug metabolizing Cyp isoform was induced
in A-998679-treated rats. The lack of a dose dependent Cyp1a
induction in rat liver is likely due to increased biological vari-
ability in whole animals compared to cells and to the fact that
the rats were exposed to the compound for 5-days while cells
were exposed for 24–48 h. Thus, rat liver had more time to
adapt and transcriptionally respond to the presence of the test
compound. Since Cyp phenotyping and inhibition experiments
revealed that both Cyp1a1 and Cyp1a2metabolize the compound
and since these enzymes were substantially induced, Cyp1a is
likely the major contributor to the loss in exposure. Hepatic
or intestinal transporters can also influence compound disposi-
tion, and A-998679 treatment increased expression of multidrug
resistance-associated protein (Mrp3) in liver and Mrp2 in small
intestine (data not shown). However, it is not known whether the
compound is a substrate of these transporters.
While the autoinduction potential of compounds is not
uncommon with the CYP3A family, there are fewer examples
Table 2 | Recombinant rat Cyp phenotype profiling after incubation
with [3H]A-998679.
Cyp isoform % parent remaining and dose
0.10µM 0.21µM
Control 100 100
1A1 0 0
1A2 0 0
2A1 100 100
2A2 90.2 77.8
2B1 87.0 34.5
2C11 78.1 28.8
2C12 100 100
2C13 100 100
2C6 91.0 88.8
2D1 91.9 91.1
2D2 100 98.1
2E1 95.5 91.9
3A1 93.9 90.3
3A2 100 94.2
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FIGURE 8 | Effect of furafylline, a specific CYP1A2 inhibitor, on the
metabolism of [3H]A-998679 in human liver microsomes. Incubations
with radiolabeled A-998679 were conducted in duplicate in human liver
microsomes in the absence or presence of increasing concentrations of
furafylline. The degree of metabolism of A-998679 steadily declined as the
level of furafylline increased, suggesting a major contribution from CYP1A2.
of this phenomenon involving CYP1A members. Along with the
PAH chemical class, TSU-68, an angiogenesis inhibitor, is an
example of a drug candidate that has been linked to autoin-
duction of CYP1A in humans and rats, resulting in increased
clearance (Kitamura et al., 2007, 2008). Other CYP1A induc-
ers, such as TCDD and omeprazole, are not substrates for
the enzyme, but nonetheless enhance its expression and activ-
ity (Ma and Lu, 2007). While CYP induction is sometimes
species-specific as in the case with omeprazole, A-998679 induced
CYP1A in rat, dog, and human hepatocytes and/or liver and
slightly inhibited the activity of human CYP1A2. Inhibition of
CYP1A2 in rats and humans has also been reported with drugs
such as fluvoxamine, ciprofloxacin, and oltipraz (Brosen et al.,
1993; Langouet et al., 1995; Sofowora et al., 2001; Granfors
et al., 2004). The pharmacologic activity of oltipraz, a can-
cer chemopreventive agent, is thought to partially involve CYP
inhibition by preventing the formation of toxic metabolites
(Sofowora et al., 2001).
Collectively, our data implicated AhR activation as the mecha-
nism responsible for the decreased plasma exposure of A-998679.
Using a gene reporter assay, the compound activated the DRE
starting at levels of ∼6μM. Genes downstream of the DRE,
including Cyp1a1 (confirmed at the protein level), Cyp1a2, Nqo1,
Aldh, and Gst, were all upregulated in rat liver treated with A-
998679. In addition, A-998679 treatment resulted in enhanced
translocation of AhR to the nucleus of HepG2 cells. Although no
direct AhR-DNA binding assays were conducted, taken together,
a weight of evidence approach suggests that direct AhR ago-
nism is the likely explanation for the interesting observations with
this compound. Since CYP1A induction was observed in cells or
tissues from rat, human, and dog, AhR activation by this com-
pound appears to be species-independent as interpreted from
data derived from in vitro hepatocyte models.
The toxicological consequence of AhR activation with A-
998679 is not known since chronic toxicity studies were not
conducted. However, the acute toxicity profile was benign and
limited to mild liver weight increase. One potential consequence
of AhR activation and subsequent Cyp1a induction is an increase
in the overall oxidative stress status of a cell, thus rendering it
more susceptible to toxic stimuli (Morel et al., 1999; Barouki
and Morel, 2001; Marchand et al., 2004). The toxicological out-
come of AhR activation may also relate to the sustainability of the
activation (Mitchell and Elferink, 2009). For instance, TCDD is
a non-labile and extremely potent activator of AhR which may
explain the compound’s enhanced toxicity profile. For A-998679
(EC50 = 16.2μM in a DRE cell reporter assay), the potency of
AhR activation is several orders of magnitude less than that of
TCDD (binding EC50 ∼pM to nM range) and PAHs (binding
EC50 ∼nM to μM range) (Nguyen and Bradfield, 2008; Mitchell
and Elferink, 2009). Rather, the potency of A-998679 is on the
same order as some endogenous ligands such as the estrogen lig-
and, equilenin (reporter assay EC50 ∼10μM) (Jinno et al., 2006)
and several prostaglandins (reporter assay EC50∼ 10–20μM)
(Seidel et al., 2001). Although A-998679 requires in vitro levels
much higher than TCDD or 3MC to elicit its effect, pheno-
typic changes in rats can be observed with relatively low doses
of compound (at least 30mg/kg with a corresponding plasma
Cmax ∼ 5μM).
Most potent AhR activators are planar molecules with the
presence of conjugated ring systems or polyhalogenation (Nguyen
and Bradfield, 2008). While A-998679 is likely planar in struc-
ture (as predicted using ChemDraw 3D), it lacks the other two
attributes of classical AhR activators, and thus its lower affinity for
AhR is not surprising. Therefore, its mechanism of AhR binding
may be more related to atypical AhR activators like the ben-
zimidazoles (e.g., omeprazole), oltipraz, or curcumin (Nguyen
and Bradfield, 2008). The former class of compounds does not
have the potential to displace [3H]-TCDD in competitive binding
assays and are thought to bind AhR outside of the TCDD pocket
(Daujat et al., 1992; Lesca et al., 1995). Further investigations
will be required to determine whether A-998679 mimics classical
methods of binding or if it has a unique mode of interaction.
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Cyp1a1 mRNA levels were increased in rat small intestine
after treatment with 30 or 100mg/kg of A-998679, but decreased
at the highest dose administered (200mg/kg). Since Cyp1a is
involved in the metabolism of A-998679, its reduced presence
may contribute to the lower clearance at high doses. The mech-
anism behind this repression is unclear. The rat jejunum gene
expression profiles and rat and human data from other reports
suggest that CYP1A1 (but not 1A2) has basal expression lev-
els much greater than in the liver, and thus enzyme induction
could be less apparent (Lin and Lu, 2001; Nishihashi et al.,
2006). AhR is expressed in small intestine and can be activated to
induce transcription of its target genes (Nishihashi et al., 2006).
However, aside from Cyp1a1, mRNAs of genes downstream from
the DRE were not induced in rat jejunum samples (data not
shown).
AhR function beyond its role as a xenosensor is complex, and
the possibility has been raised that some ligands may regulate
the effects of AhR diversely between tissue types (Mitchell and
Elferink, 2009; Abel and Haarmann-Stemmann, 2010). This may
partially explain the repression effect in jejunum with high lev-
els of A-998679, but further investigation will be required for
a full understanding. Repression of several Cyp isoforms can
be associated with an inflammatory state, but no evidence of
inflammation was apparent (Lee et al., 2010). Also, the AhR
repressor protein (Ahrr), which inhibits AhR function, is con-
stitutively expressed at higher levels in the small intestine of
male rats compared to other tissues (Nishihashi et al., 2006).
Consequently, the AhR activation potential of A-998679 may
be diminished in small intestine as a result of the heightened
presence of Ahrr.
In the present study, the mechanism behind the increased
clearance in rats over time of A-998679 was identified. The
compound activates AhR, possibly through direct binding and
agonism for AhR, with subsequent nuclear translocation and
induction of its downstream genes, including Cyp1a. This was
identified as a rare autoinduction phenomenon since Cyp1a is
involved in the metabolism of the compound. In addition, at
higher doses (200mg/kg/day), the capacity of Cyp1a was satu-
rated which maintained the compound plasma levels. Evidence
from human liver microsomes suggests that A-998679 can also act
as a weak inhibitor of CYP1A2, which could contribute to higher
levels. These interesting molecular properties, along with its novel
chemical structure distinct from classical PAHs, may allow for A-
998679 to be further investigated as a tool compound in studies
involving AhR and CYP biology.
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APPENDIX
Table A1 | Primer and probe sequences used for RT-PCR assays.
Species mRNA Forward primer Probe Reverse primer
Human CYP1A1 GAT TGG GCA CAT GCT GAC C TGG GAA AGA ACC CGC ACC TGG C CTG TCA AGG ATG AGC CAG CA
CYP1A2 TGG CTT CTA CAT CCC CAA GAA A CTG CCA CTG GTT TAC GAA GAC ACA CCA CAG CTC TGG GTC ATG GT
Rat Cyp1a1 GCC ATC TGC TGA GGC TCA AC TCT TCC AAC ATG GGT TTA TGA CAC T GGT GCT ACA CCC CCA CAT G
Cyp1a2 TGG CCG TGT TGT CAT TGG TGT TCC GCC CAG AGC GGT TTC CAT GAT GAG AAG CAG TGG AAA GA
Dog CYP1A2 CAA GCG CCG GTG CAT AG TCT CCC ACT TGG CCA GGA CCT CT GCA AGA TGG CTA GGA AGA GGA A2
28S TTC ACC AAG CGT TGG ATT GTT TCA CGA CGG TCT AAA CCC AGC TCA CG TGT CTG AAC CTG CGG TTC CT
Table A2 | Incubation conditions used to evaluate the inhibitory effect of A-998679 on specific CYP isoforms.
Isoform Probe substrate Substrate concentration (µM) Human liver microsomes [protein] (mg/ml) Incubation (min)
CYP1A2 Phenacetin 25 0.1 30
CYP2C9 Diclofenac 5 0.05 10
CYP2C19 S-Mephenytoin 22 0.2 40
CYP2D6 Dextromethorphan 2.5 0.05 30
CYP3A4 Midazolam 4 0.05 10
Table A3 | Mobile phase composition.
Isoform Mobile phase A Mobile phase B
CYP1A2 Water with 0.05% acetic acid MeOH:ACN (20:80) with 0.05% acetic acid
CYP2C9 Water:MeOH (95:5) with 1mM ammonium acetate ACN:MeOH (50:50) with 1mM ammonium acetate
CYP2C19 Water:MeOH (95:5) with 1mM ammonium acetate ACN:MeOH (50:50) with 1mM ammonium acetate
CYP2D6 Water with 0.05% acetic acid MeOH:ACN (20:80) with 0.05% acetic acid
CYP3A4 Water with 0.1% formic acid MeOH with 0.% formic acid
Table A4 | Elution conditions used for each specific to each analyte.
1A2 2C9 2C19 2D6 3A4
Time(min) %B Time(min) %B Time(min) %B Time(min) %B Time(min) %B
0 0 0 15 0 10 0 5 0 20
0.5 0 0.5 15 0.5 10 0.1 5 0.5 20
0.6 40 1.5 95 2.2 100 2 60 3 100
2.4 40 2.5 95 2.9 100 2.1 100 3.1 20
2.5 100 2.6 15 3.0 10 2.7 100 3.6 20
3.0 100 3.0 15 3.5 10 2.8 5 – –
3.1 0 – – – – 3.4 5 – –
3.5 0 – – – – – – – –
Flow rate: 0.5ml/min Flow rate: 0.45ml/min Flow rate: 0.65ml/min Flow rate: 0.7ml/min Flow rate: 0.5ml/min
for 2.4min, followed
by 0.7ml/min
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Table A5 | Specific multiple reaction monitoring (MRM) transitions monitored to quantify the analyte of interest were as follows.
Isoform Metabolite Metabolite MRM Internal standard (IS) IS MRM Ionization mode
CYP1A2 Acetaminophen 152 → 110 Acetanilide 136 → 94 Positive
CYP2C9 4-hydroxy diclofenac 310 → 266 Mefenamic acid 240 → 196 Negative
CYP2C19 4-hydroxy mephenytoin 233 → 190 Diphenyl hydantoin 251 → 102 Negative
CYP2D6 Dextrorphan 258 → 157 Levallorphan 284 → 157 Positive
CYP3A4 1-hydroxy midazolam 342 → 203 α-hydroxytriazolam 359 → 176 Positive
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